The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has
been a major focus of oncology research. The p53 protein is a transcription factor that can …

From 1994 through 2021, The International Agency for Research on Cancer (IARC) and the
World Health Organization maintained a comprehensive database on variations in the tumor …

Simple Summary Li–Fraumeni Syndrome (LFS) is a rare tumor predisposition syndrome in
which the tumor suppressor TP53 gene is mutated in the germ cell population. LFS patients …

Missense driver mutations in cancer are concentrated in a few hotspots. Various
mechanisms have been proposed to explain this skew, including biased mutational …

This Special Issue covers a broad topic on the role of the p53 protein family in cancer. The
p53 protein is a critical sensor of cellular stress that has evolved in multicellular organisms …

Rare pathogenic variants in known breast cancer-susceptibility genes and known common
susceptibility variants do not fully explain the familial aggregation of breast cancer. To …

Bone sarcoma is a rare component of malignant solid tumors that accounts for only~ 0.2% of
malignancies. Bone sarcomas present various histological types, and genomic mutations …

PURPOSE Establishing accurate age-related penetrance figures for the broad range of
cancer types that occur in individuals harboring a pathogenic germline variant in the TP53 …

Recently, the WHO-5 and the ICC 2022 criteria have emphasized poor prognosis in
AML/MDS patients with multi-hit TP53 mutations, whereas mutated TP53 plays a critical role …

Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-
Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by …